Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.68 |
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855522 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Dectaflur SCHEMBL20875746 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11850135 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Dectaflur SCHEMBL21052121 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL25409164 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL21060609 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL23621182 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL22677777 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Dectaflur SCHEMBL21052097 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Dectaflur SCHEMBL21052096 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9017726-B2 | Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-28 | — | — | US | disclosed |
| US-9017726-B2 | Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-28 | — | — | US | disclosed |
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | Korean Institute of Science and Technology of Seoul, Republic of Korea | 2012-05-17 | — | — | US | disclosed |
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | Korean Institute of Science and Technology of Seoul, Republic of Korea | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | PHOSPHO1, HSPA2, FEM1B | DNM1 3966/4885MEN1 168/4885KMT2A 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.